Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059131 | 0.86 | AURKA (0.56) | AURKATBK1IKBKECYP3A4AURKB | |
| SCHEMBL4059275 | 0.86 | AURKA (0.58) | AURKACHEK2MEN1KMT2APRMT5 | |
| SCHEMBL4056737 | 0.86 | SCD (0.59) | AURKACHEK2TBK1IKBKEKMT2A | |
| SCHEMBL4055492 | 0.85 | TBK1 (0.53) | AURKACHEK2TBK1IKBKEPRMT5 | |
| SCHEMBL4054859 | 0.85 | TBK1 (0.54) | AURKACHEK2TBK1IKBKEMEN1 | |
| SCHEMBL4054755 | 0.81 | AURKA (0.53) | AURKATBK1IKBKECYP3A4KIT | |
| SCHEMBL18764092 | 0.80 | HDAC6 (0.54) | AURKACHEK2TBK1IKBKEKMT2A | |
| SCHEMBL13607981 | 0.80 | CHEK2 (0.54) | CHEK2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL4058315 | 0.79 | AURKA (0.52) | AURKACHEK2TBK1IKBKECYP3A4 | |
| SCHEMBL4049683 | 0.79 | SCD (0.62) | AURKATBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | AURKA 247/4885CHEK2 184/4885TBK1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.